natgillin/translations-raw huggingface dataset:
Patients who are unable to swallow the tablet(s) whole may disperse the tablet(s) in a glass of water.
Bolniki, ki ne morejo pogoltniti cele tablete (tablet), jo (jih) lahko dispergirajo v kozarcu vode.
Patients who are unable to swallow the tablet(s) whole may disperse the tablet(s) in a glass of water.
Bolniki, ki ne morejo pogoltniti cele tablete, jo lahko dispergirajo v kozarcu vode.
Patients who are unable to tolerate tadalafil 5 mg for the treatment of benign prostatic hyperplasia should consider an alternative therapy as the efficacy of tadalafil 2.5mg for the treatment of benign prostatic hyperplasia has not been demonstrated.
Bolniki, ki ne prenašajo tadalafila 5 mg za zdravljenje benigne hiperplazije prostate, naj razmislijo o alternativnem zdravljenju, saj učinkovitost tadalafila 2,5 mg za zdravljenje benigne hiperplazije prostate ni bila dokazana.
Patients who are undergoing chemotherapy and/or radiotherapy, who are taking steroids, who are undergoing dental surgery, who do not receive routine dental care, who have gum disease, who are smokers, or who were previously treated with a bisphosphonate (used to treat or prevent bone disorders) may have a higher risk of developing osteonecrosis of the jaw.
Pri bolnikih, ki se zdravijo s kemoterapijo in/ali obsevanjem, ki jemljejo steroide, imajo zobozdravstveno operacijo, ki nimajo redne zobozdravstvene oskrbe, ki imajo obolenje dlesni, ki kadijo ali ki so se v preteklosti zdravili z difosfonati (uporabljajo se za zdravljenje ali preprečevanje obolenj kosti), je lahko tveganje za pojav osteonekroze čeljusti večje.
Patients who attained a viral load of less than 50 HIV-1 RNA copies/ml after 48 weeks of treatment were considered to have responded to treatment.
Za bolnike, pri katerih se je po 48 tednih zdravljenja virusno breme zmanjšalo na manj kot 50 HIV-1 RNA kopij/ml, se je štelo, da so se na zdravljenje odzvali.
Patients who attempted to reduce or discontinue baseline therapy, n (%)b p-value a
Bolniki pri katerih so izhodiščno obliko zdravljenja poskušali zmanjšati ali ukiniti, n (%)b vrednost pa
Patients who cannot perceive or respond to thirst
bolniki, ki žeje ne zaznavajo ali se nanjo ne morejo odzvati
Patients who cannot perceive thirst
bolniki, ki ne zaznavajo žeje
Patients who cannot swallow tablets may crush the tablets and add them to a small amount of food or drink immediately before swallowing it.
Bolniki, ki ne morejo pogoltniti cele tablete, naj jo zdrobijo in jo neposredno pred zaužitjem zmešajo z majhno količino hrane ali pijače.
Patients who cannot take phenylalanine should note that ABILIFY orodispersible tablets contain aspartame, which is a source of phenylalanine.
Bolniki, ki ne smejo uživati fenilalanina, se morajo zavedati, da orodisperzibilne tablete ABILIFY vsebujejo aspartam, ki je vir fenilalanina.
Patients who cannot undergo primary PCI within one hour as recommended by guidelines and receive tenecteplase as primary coronary recanalization treatment should be transferred without delay to a coronary intervention capable facility for angiography and timely adjunctive coronary intervention within 6-24 hours or earlier if medically indicated (see section 5.1 STREAM study)
Bolnike, pri katerih primarne perkutane koronarne intervencije ni mogoče opraviti v eni uri, kot priporočajo smernice, in prejemajo tenekteplazo za primarno koronarno rekanalizacijo, je treba brez odlašanja premestiti v enoto, ki je opremljena za izvajanje koronarnih intervencij, opraviti angiografijo in pravočasno izvesti dodatno koronarno intervencijo v 6 do 24 urah ali prej, če je medicinsko indicirano (glejte poglavje 5.1 študija STREAM).
Patients who carry the HLA-B*57:01 allele have an increased risk of pazopanib-associated ALT elevations.
Tveganje za zvišanje vrednosti ALT zaradi pazopaniba je lahko povečano tudi pri bolnikih, ki so nosilci alela HLA- B*57:01.
Patients who commence treatment on the parenteral formulation may be switched to the oral one when clinically indicated.
Bolniki, ki so začeli zdravljenje s parenteralno obliko zdravila, lahko preidejo na peroralno obliko, ko je to klinično indicirano.
Patients who commence treatment on the parenteral formulation may be switched to the oral presentation when clinically indicated.
Bolniki, ki so začeli zdravljenje s parenteralno obliko zdravila, lahko preidejo na peroralno obliko, ko je to klinično indicirano.
Patients who complete 9 cycles or who are unable to complete the combination therapy due to intolerance are treated with lenalidomide alone, 10 mg/day orally on days 1-21 of repeated 28-day cycles given until disease progression.
Bolniki, ki dokončajo 9 ciklov ali ki niso sposobni dokončati kombiniranega zdravljenja zaradi intolerance, naj se zdravijo samo z lenalidomidom, 10 mg/dan peroralno od 1. do 21. dne, v ponavljajočih se 28-dnevnih ciklih, ki ga dajemo do napredovanja bolezni.
Patients who completed 9 cycles or who were unable to complete 9 cycles due to intolerance proceeded to maintenance monotherapy starting with lenalidomide 10 mg orally on days 1-21 of repeated 28-day cycles until disease progression.
Bolniki, ki so dokončali 9 ciklov ali ki niso mogli dokončati 9 ciklov zaradi intolerance, so nadaljevali z vzdrževalno monoterapijo, najprej z lenalidomidom 10 mg peroralno od 1. do 21. dne ponavljajočih se 28-dnevnih ciklov do napredovanja bolezni.
Patients who completed Part I of the study and achieved at least a JIA ACR30 response at week 16 compared to baseline were eligible to enter the blinded withdrawal period (Part II) of the study.
Bolniki, ki so zaključili I. del študije in so po 16. tednih dosegli najmanj odziv JIA ACR 30 glede na izhodiščno vrednost, so se lahko vključili v slepo fazo odtegnitve (II. del študije).
Patients who completed the initial 24-week study period were eligible to enter a controlled 28 week long-term study extension (52 weeks).
Bolniki, ki so dokončali začetno 24-tedensko obdobje študije, so lahko vstopili v kontrolirano 28-tedensko dolgoročno podaljšanje študije (52 tednov).
Patients who could walk more than 30 meters (m) but less than 325 m in a 6 Minute Walk Test (MWT) at baseline were enrolled in the trial.
V preskušanje so bili vključeni bolniki, ki so v šestminutnem testu hoje na začetku zdravljenja lahko prehodili več kot 30 metrov (m) in manj kot 325 metrov (m).
Patients who develop a Grade 3 QTc prolongation should stop taking XALKORI until recovery to Grade ≤1, then resume at 200 mg twice daily.
Bolniki, pri katerih se pojavi podaljšanje intervala QTc stopnje 3, morajo jemanje zdravila XALKORI začasno prekiniti, dokler ne pride do izboljšanja na stopnjo ≤ 1, nato pa z zdravljenjem nadaljevati z odmerkom 200 mg dvakrat na dan.
Patients who develop a Grade 4 QTc prolongation should stop taking XALKORI permanently.
Bolniki, pri katerih se pojavi podaljšanje intervala QTc stopnje 4, morajo jemanje zdravila XALKORI trajno prekiniti.
Patients who develop a new infection while undergoing treatment with Humira, should be monitored closely and undergo a complete diagnostic evaluation.
Bolnike, pri katerih se med zdravljenjem z zdravilom Humira pojavi nova okužba, je treba natančno nadzirati in opraviti morajo popolno diagnostično obravnavo.
Patients who develop a new infection while undergoing treatment with Inflectra, should be monitored closely and undergo a complete diagnostic evaluation.
Tiste bolnike, pri katerih se med zdravljenjem z zdravilom Inflectra pojavi nova okužba, je treba natančno spremljati in pri njih opraviti celotni diagnostični postopek.
Patients who develop a new infection while undergoing treatment with Remsima, should be monitored closely and undergo a complete diagnostic evaluation.
Tiste bolnike, pri katerih se med zdravljenjem z zdravilom Remsima pojavi nova okužba, je treba natančno spremljati in pri njih opraviti celotni diagnostični postopek.
Patients who develop a new infection while undergoing treatment with Simponi should be monitored closely and undergo a complete diagnostic evaluation.
Bolnike, pri katerih se med zdravljenjem z zdravilom Simponi pojavi nova okužba, je treba natančno spremljati in pri njih opraviti vse diagnostične preiskave.
Patients who develop a single value of corrected ECG QTc interval of at least 500 msec should stop taking vandetanib.
Bolniki, ki se jim na EKG pojavi ena sama vrednost korigiranega intervala QTc v vrednosti vsaj 500 ms, morajo prenehati z jemanjem vandetaniba.
Patients who develop acute renal failure must discontinue Pradaxa (see section 4.3).
Bolniki, pri katerih se razvije akutna ledvična odpoved, morajo zdravilo Pradaxa prenehati jemati (glejte poglavje 4.3).
Patients who develop adverse reactions should receive appropriate symptomatic treatment.
Bolniki, pri katerih se pojavijo neželeni učinki, morajo biti deležni ustreznega simptomatskega zdravljenja.
Patients who develop antibodies to exenatide tend to have more injection site reactions (for example: redness of skin and itching), but otherwise similar rates and types of adverse events as those with no anti- exenatide antibodies.
Pri bolnikih, ki so razvili protitelesa proti eksenatidu, se je pogosteje pojavila reakcija na mestu injiciranja (na primer rdečica na koži ali srbenje), sicer pa so imeli podobne stopnje in vrste neželenih učinkov kot tisti brez protiteles proti eksenatidu.
Patients who develop arrhythmic symptoms or new onset of dyspnoea should be evaluated clinically and if indicated have an electrocardiogram (ECG) performed.
Bolnike, pri katerih se pojavijo simptomi aritmije ali se na novo pojavi zadihanost, je treba klinično pregledati in jim po potrebi posneti elektrokardiogram (EKG).
Patients who develop clinical or laboratory evidence of haemolysis during micafungin therapy should be monitored closely for evidence of worsening of these conditions and evaluated for the risk/benefit of continuing micafungin therapy.
Bolnike, pri katerih se v času zdravljenja z mikafunginom pojavijo klinični ali laboratorijski dokazi hemolize, je treba skrbno spremljati zaradi možnosti poslabšanja stanja ter oceniti razmerje med tveganjem in koristjo pri nadaljnjem zdravljenju z mikafunginom.
Patients who develop fatigue, somnolence or confusion during treatment with PegIntron are cautioned to avoid driving or operating machines.
Bolniki, ki postanejo utrujeni, zaspani ali zmedeni med zdravljenjem z zdravilom PegIntron, naj ne vozijo in ne upravljajo s stroji.
Patients who develop fatigue, somnolence or confusion during treatment with ViraferonPeg are cautioned to avoid driving or operating machines.
Bolniki, ki postanejo utrujeni, zaspani ali zmedeni med zdravljenjem z zdravilom ViraferonPeg, naj ne vozijo in ne upravljajo s stroji.
Patients who develop IgE antibodies to alglucosidase alfa appear to be at a higher risk for the occurrence of IARs when Myozyme is re- administered (see section 4.8).
Pri bolnikih, kjer se razvijejo protitelesa IgE proti alglukozidazi alfa, dozdevno obstaja večje tveganje za pojavnost IARs ob ponovnem dajanju zdravila Myozyme (glejte poglavje 4.8).
Patients who develop increased transaminase levels should be monitored closely until the abnormalities resolve.
Bolnike, pri katerih se razvijejo zvišane ravni transaminaz, je treba skrbno spremljati, dokler nenormalnosti ne izzvenijo.
Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue Eucreas.
Bolniki, pri katerih pride do ikterusa ali drugih znakov, ki nakazujejo moteno delovanje jeter, morajo prekiniti zdravljenje z zdravilom Eucreas.
Patients who develop Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin must not receive Retacrit or any other erythropoietin (see section 4.4).
Bolniki, pri katerih po zdravljenju s katerimkoli eritropoetinom pride do čiste aplazije rdečih krvnih celic (PRCA - "Pure Red Cell Aplasia"), zdravila Retacrit ali kateregakoli drugega eritropoetina ne smejo dobivati (glejte poglavje 4.4).
Patients who develop pure red cell aplasia (PRCA) following treatment with any erythropoietin should not receive Abseamed or any other erythropoietin (see section 4.4).
Bolniki, pri katerih se po zdravljenju s katerim koli eritropoetinom razvije aplazija rdečih krvnih celic (PRCA – pure red cell aplasia), ne smejo dobivati zdravila Abseamed ali katerega koli drugega eritropoetina (glejte poglavje 4.4).
Patients who develop pure red cell aplasia (PRCA) following treatment with any erythropoietin should not receive Binocrit or any other erythropoietin (see section 4.4).
Bolniki, pri katerih se po zdravljenju s katerim koli eritropoetinom razvije aplazija rdečih krvnih celic (PRCA – pure red cell aplasia), ne smejo dobivati zdravila Binocrit ali katerega koli drugega eritropoetina (glejte poglavje 4.4).
Patients who develop pure red cell aplasia (PRCA) following treatment with any erythropoietin should not receive Epoetin alfa HEXAL or any other erythropoietin (see section 4.4).
Bolniki, pri katerih se po zdravljenju s katerim koli eritropoetinom razvije aplazija rdečih krvnih celic (PRCA – pure red cell aplasia), ne smejo dobivati zdravila Epoetin alfa HEXAL ali katerega koli drugega eritropoetina (glejte poglavje 4.4).
Patients who develop these signs and symptoms while receiving Cubicin should undergo prompt medical evaluation, including, if appropriate, bronchoalveolar lavage, to exclude other causes (e.g. bacterial infection, fungal infection, parasites, other medicinal products).
Bolnike, pri katerih v času jemanja zdravila Cubicin pride do navedenih znakov in simptomov, je treba takoj preiskati in jim, če je treba, izvesti bronhoalveolarno lavažo, da bi lahko izključili druge vzroke bolezni (na primer bakterijsko okužbo, glivično okužbo, parazite ali druga zdravila).
Patients who did not have evidence of at least a minor erythroid response after 16 weeks were to be discontinued from treatment.
Bolnikom brez znakov vsaj manjšega eritroidnega odziva po 16 tednih, so zdravljenje ukinili.
Patients who did not respond discontinued protocol treatment after 4 weeks.
Pri bolnikih, ki se niso odzvali, so po 4 tednih zdravljenje prekinili.
Patients who did not respond to infliximab at week 8 (n = 15) received no further drug and returned for safety follow-up.
Bolniki, ki se do 8. tedna niso odzvali na infliksimab (n = 15), niso več prejemali zdravila in so se vrnili na kontrolni pregled glede varnosti.
Patients who did not respond to infliximab at week 8 (n=15) received no further drug and returned for safety follow-up.
Bolniki, ki se do 8. tedna niso odzvali na infliksimab (n = 15), niso več prejemali zdravila in so se vrnili na kontrolni pregled glede varnosti.
Patients who did not respond to infliximab at week 8 (n=15) received no further medicinal product and returned for safety follow- up.
Bolniki, ki se do 8. tedna niso odzvali na infliksimab (n = 15), niso več prejemali zdravila in so se vrnili na kontrolni pregled glede varnosti.
Patients who did not undergo transplant
bolniki brez presaditve
Patients who discontinued one or more components of treatment because of an adverse event were permitted to continue therapy with the other treatment component(s) until disease progression or unacceptable toxicity.
Bolniki, ki so zaradi neželenega učinka prenehali uporabljati eno ali več komponent zdravljenja, so lahko nadaljevali zdravljenje z drugimi komponentami zdravljenja do napredovanja bolezni ali nesprejemljive toksičnosti.
Patients who do not experience a meaningful benefit should be re- evaluated and discontinuation of therapy be considered.
Bolnice, pri katerih ni bistvenega izboljšanja, je treba ponovno oceniti in pretehtati možnost prekinitve zdravljenja.
patients who do not have adequate skin covering or blood supply at the operation site;
bolnikih, ki na mestu operativnega posega nimajo zadostne prekritosti s kožo ali prekrvavljenosti;
Patients who do not respond to initial treatment should not be re-treated with Ilaris.
Bolniki, ki se ne odzovejo na začetno zdravljenje, zdravila Ilaris ne smejo ponovno prejeti.
Patients who experience a severe decrease of vision (equivalent to 4 lines or more) within one week after treatment should not be re-treated, at least until their vision has completely recovered to pre- treatment level and the potential benefits and risks of subsequent treatment have been carefully considered by the treating physician.
Pri bolnikih, ki se jim v enem tednu po zdravljenju vid močno poslabša (ustrezno 4 vrstam ali več), se zdravljenja ne sme ponoviti vsaj toliko časa, dokler se jim vid ne izboljša na raven pred zdravljenjem in dokler zdravnik skrbno ne pretehta možnih koristi in tveganj nadaljnjega zdravljenja.
Patients who experience a significant reduction in urinary free cortisol [UFC] levels should continue to receive Signifor for as long as benefit is derived.
Bolniki, pri katerih pride do pomembnega znižanja koncentracije prostega kortizola v urinu (angl. urinary free cortisol, UFC), bi morali še naprej prejemati zdravilo Signifor, dokler jim to koristi.
Patients who experience adverse reactions during treatment should wait for these to resolve before driving or operating machines.
Bolniki, ki imajo med zdravljenjem neželene učinke, naj počakajo, da minejo, preden spet vozijo ali upravljajo s stroji.
Patients who experience adverse reactions during treatment should wait for these to resolve before driving or operating machines.
Bolniki, ki med zdravljenjem doživijo neželene učinke, morajo počakati, da izzvenijo, preden vozijo ali upravljajo s stroji.
Patients who experience bortezomib-related neuropathic pain and/or peripheral neuropathy are to be managed as presented in Table 1 (see section 4.4).
Bolnike, ki imajo nevropatično bolečino in/ali periferno nevropatijo v povezavi z jemanjem bortezomiba, zdravite v skladu s preglednico 1 (glejte poglavje 4.4).
Patients who experience dizziness or visual difficulties during therapy must not drive or operate machinery.
Bolniki, pri katerih se pojavijo omotice ali motnje vida med terapijo, ne smejo voziti ali upravljati s stroji.
Patients who experience dizziness should use caution when driving, cycling or using machines.
Bolniki, pri katerih se pojavlja omotica, morajo biti pri vožnji, kolesarjenju ali upravljanju s stroji previdni.
Patients who experience dizziness, vertigo or somnolence after receiving Dynastat should refrain from driving or operating machines.
Bolniki, pri katerih se po prejemu zdravila Dynastat pojavi omotica, vrtoglavica ali zaspanost, ne smejo voziti ali upravljati s stroji.
Patients who experience febrile netutropeania and/or neutropenic infection should have their docetaxel dose reduced to 60 mg/m2 in all subsequent cycles (see sections 4.4 and 4.8).
Bolnicam, ki se jim pojavi febrilna nevtropenija in/ali nevtropenična okužba, je treba odmerek docetaksela v vseh nadaljnjih ciklusih zmanjšati na 60 mg/m2 (glejte poglavji 4.4 in 4.8).
Patients who experience febrile neutropenia and/or neutropenic infection should have their docetaxel dose reduced to 60 mg/m2 in all subsequent cycles (see sections 4.4 and 4.8).
Bolnicam, ki se jim pojavi febrilna nevtropenija in/ali nevtropenična okužba, je treba odmerek docetaksela v nadaljnjih ciklusih zmanjšati na 60 mg/m2 (glejte poglavji 4.4. in 4.8).
Patients who experience febrile neutropenia and/or neutropenic infection should have their docetaxel dose reduced to 60 mg/m2 in all subsequent cycles (see sections 4.4 and 4.8).
Pri bolnicah, pri katerih se je razvila febrilna nevtropenija in/ali nevtropenična okužba je treba odmerek docetaksela zmanjšati na 60 mg/m² v vseh naslednjih ciklusih zdravljenja (glejte poglavji 4.4 in 4.8).
Patients who experience febrile neutropenia and/or neutropenic infection should have their docetaxel dose reduced to 60 mg/m² in all subsequent cycles (see sections 4.4 and 4.8).
Bolnicam, ki se jim pojavi febrilna nevtropenija in/ali nevtropenična okužba, je treba odmerek docetaksela v nadaljnjih ciklusih zmanjšati na 60 mg/m2 (glejte poglavji 4.4. in 4.8).
Patients who experience febrile neutropenia and/or neutropenic infection should have their docetaxel dose reduced to 60 mg/m² in all subsequent cycles (see sections 4.4 and 4.8).
Bolnikom, ki se jim pojavi febrilna nevtropenija in/ali nevtropenična okužba, je treba odmerek docetaksela v nadaljnjih ciklusih zmanjšati na 60 mg/m2 (glejte poglavji 4.4 in 4.8).
Patients who experience febrile neutropenia and/or neutropenic infection should have their docetaxel dose reduced to 60 mg/m² in all subsequent cycles (see sections 4.4 and 4.8).
Bolnikom, ki se jim pojavi febrilna nevtropenija in/ali nevtropenična okužba,je treba odmerek docetaksela v vseh nadaljnjih ciklusih zmanjšati zmanjšati na 60 mg/m2 (glejte poglavji 4.4 in 4.8).
Patients who experience severe neutropenia (neutrophils
Če se med zdravljenjem z zdravilom Paxene pri bolnicah pojavi huda periferna nevtropenija (število nevtrofilcev
Patients who experience side effects such as stomach problems, light-sensitive skin reactions or significant changes in the levels of liver enzymes may need to have their dose reduced at least temporarily.
Pri bolnikih, pri katerih se pojavijo neželeni učinki, kot so težave z želodcem, reakcije kožne preobčutljivosti na svetlobo ali večje spremembe ravni jetrnih encimov, bo morda treba odmerek vsaj začasno zmanjšati.
Patients who experience such reactions that are considered TRISENOX related must resume treatment only after resolution of the toxic event or after recovery to baseline status of the abnormality that prompted the interruption.
Pri bolnikih, pri katerih se pojavijo take reakcije, za katere menite, da so povezane z zdravilom TRISENOX, lahko nadaljujete zdravljenje šele po odpravi toksičnosti ali po vrnitvi anomalije, zaradi katere ste prekinili zdravljenje, na izhodiščno vrednost.
Patients who fail to achieve this level of response within the described one month test period should be considered non-responsive and should not receive treatment with Kuvan.
Bolnike, pri katerih v opisanem enomesečnem preizkusnem obdobju te stopnje odziva ni bilo mogoče doseči, je treba obravnavati kot neodzivne in se jih z zdravilom Kuvan ne sme zdraviti.
Patients who failed previous therapy: prior null responders, partial responders and relapsers to interferon and ribavirin therapy
Bolniki, pri katerih predhodno zdravljenje ni bilo uspešno: na predhodno zdravljenje z interferonom in ribavirinom popolnoma neodzivni bolniki, delno odzivni bolniki in bolniki z recidivom
Patients who failed to demonstrate response at Week 6 in GEMINI II were retained in the study and received vedolizumab every four weeks.
Bolniki brez ugotovljenega odziva v 6. tednu v študiji GEMINI II so ostali v študiji in so prejemali vedolizumab na vsake štiri tedne.
Patients who failed to demonstrate response at Week 6 remained in the study and received vedolizumab every four weeks.
Bolniki, pri katerih niso uspeli dokazati odziva v 6. tednu, so ostali v študiji in prejemali vedolizumab na vsake štiri tedne.
Patients WHO FC at baseline was II (31%) and FC III (69%).
Izhodiščno so bili bolniki v II. (31 %) in III. (69 %) funkcijskem razredu po SZO.
Patients who forget a dose, are advised to take it upon discovery and then resume their usual once- daily dosing schedule.
Bolniki, ki pozabijo odmerek, naj ga vzamejo, ko to ugotovijo, in potem nadaljujejo s predpisanim odmerjanjem enkrat na dan.
Patients who had a BCVA score of <84 OR retinal thickness > 250 microns by optical coherence tomography OCT and in the investigator’s opinion treatment would not put the patient at risk; were eligible to receive an OZURDEX treatment in an open label extension.
Bolniki, pri katerih je bil rezultat BCVA < 84 ALI debelina mrežnice > 250 mikronov, ki so jo izmerili z optično koherenčno tomografijo, in pri katerih po mnenju raziskovalca zdravljenje ne bi pomenilo tveganja, so izpolnjevali merila za prejem zdravljenja z zdravilom OZURDEX v odprtem podaljšanju študije.